The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

The Biden OMB’s new report on federal regulations leaves many costs unquantified, while Trump’s new term promises a ...

Total revenues for the fiscal first quarter were $0.87 million ... screening technology to the United States market in the 2025 calendar year. * The customer employee estimate of 152,000 employees ...

Business Highlights and Fiscal 2025 to Fiscal 2024 Second ... and steel production expected by the end of the first calendar quarter of 2025. As of September 30, 2024, the cumulative investment ...

All comparisons are to the first quarter of fiscal 2024 ... and we expect our EV revenue to continue to grow throughout calendar 2025, as the total number of car models using a Wolfspeed ...

For the first quarter of the 2025 fiscal year, the management team at ... it has fallen to 3.4. By the end of this calendar year, the company is hoping to bring its net leverage ratio down to ...

In the second quarter of its 2025 fiscal year, Novelis incurred $61 million in charges ... Bay Minette is expected to begin commissioning in the second half of the 2026 calendar year. It will have an ...

as amended (the “Company”), today is pleased to announce the declaration of distributions on shares of the Company’s common and preferred stock for the first calendar quarter of 2025 (fiscal ...

"Our first quarter fiscal 2025 results reflect the continued momentum ... Holdings"), which is expected to close towards the end of calendar year 2024, subject to customary closing conditions ...

Michael Garcia, the Company’s Chief Executive Officer, commented, “Our fiscal second quarter results ... EAF by the end of the first quarter 2025, positioning us among North America’s ...